{"title":"经直肠超声引导前列腺检查患者病理结果与疼痛评分关系的评价","authors":"D. Bolat, M. E. Aydın, B. Gunlusoy, T. Değirmenci, Y. K. Topcu, İbrahim Küçüktürkmen, Y. Ceylan, E. Şefik","doi":"10.4274/UOB.666","DOIUrl":null,"url":null,"abstract":"© Üroonkoloji Bülteni, Ga le nos Ya yı ne vi ta ra fın dan ba sıl mış tır. Bu makale “Creative Commons Alıntı-Gayriticari-Türetilemez 4.0 Uluslararası Lisansı (CC BY-NC 4.0)” ile lisanslanmıştır. Objectives: In this study, we assessed the relationship between pain scores and the pathology results of patients who underwent transrectal ultrasound-guided prostate biopsy (TRUS-PBx). Materials and Methods: A total of 198 patients who underwent prostate biopsy between October 2014 and April 2015 due to abnormal digital rectal examination findings and/or high prostatespecific antigen (PSA) levels (≥2.5 ng/dL) were included in this study. Before the biopsy procedure, all patients underwent finger-guided transperineal periprostatic block with 10 mL of 2% prilocaine. A 10-point linear visual analogue scale (VAS) was used to assess the pain arising from probe insertion (VAS-1) and prostate sampling (VAS-2). After receiving the pathology results, the patients were grouped according to the presence of prostate cancer: Group 1: patients without prostate cancer and Group 2: patients with prostate cancer. Results: The mean age of the patients was 64±7.3 (43-83) years, and the mean PSA value was 12.5±18.3 (0.6-142) ng/dL. Prostate cancer detection rate was 22.7%. The mean VAS-1 score in Group 1 and group 2 was 1.6±1.8 and 2.0±2.5, respectively (p=0.209). The mean VAS-2 score in Group 1 and Group 2 was 2.5±2.4 and 2.6±2.6, respectively (p=0,725). Conclusion: The pain felt during TRUS-PBx is not related with the presence of prostate cancer on biopsy pathology.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2016-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Evaluation of the Relationship between Pathology Results and Pain Scores in Patients Who Underwent Transrectal Ultrasound-Guided Prostate\",\"authors\":\"D. Bolat, M. E. Aydın, B. Gunlusoy, T. Değirmenci, Y. K. Topcu, İbrahim Küçüktürkmen, Y. Ceylan, E. Şefik\",\"doi\":\"10.4274/UOB.666\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"© Üroonkoloji Bülteni, Ga le nos Ya yı ne vi ta ra fın dan ba sıl mış tır. Bu makale “Creative Commons Alıntı-Gayriticari-Türetilemez 4.0 Uluslararası Lisansı (CC BY-NC 4.0)” ile lisanslanmıştır. Objectives: In this study, we assessed the relationship between pain scores and the pathology results of patients who underwent transrectal ultrasound-guided prostate biopsy (TRUS-PBx). Materials and Methods: A total of 198 patients who underwent prostate biopsy between October 2014 and April 2015 due to abnormal digital rectal examination findings and/or high prostatespecific antigen (PSA) levels (≥2.5 ng/dL) were included in this study. Before the biopsy procedure, all patients underwent finger-guided transperineal periprostatic block with 10 mL of 2% prilocaine. A 10-point linear visual analogue scale (VAS) was used to assess the pain arising from probe insertion (VAS-1) and prostate sampling (VAS-2). After receiving the pathology results, the patients were grouped according to the presence of prostate cancer: Group 1: patients without prostate cancer and Group 2: patients with prostate cancer. Results: The mean age of the patients was 64±7.3 (43-83) years, and the mean PSA value was 12.5±18.3 (0.6-142) ng/dL. Prostate cancer detection rate was 22.7%. The mean VAS-1 score in Group 1 and group 2 was 1.6±1.8 and 2.0±2.5, respectively (p=0.209). The mean VAS-2 score in Group 1 and Group 2 was 2.5±2.4 and 2.6±2.6, respectively (p=0,725). Conclusion: The pain felt during TRUS-PBx is not related with the presence of prostate cancer on biopsy pathology.\",\"PeriodicalId\":40816,\"journal\":{\"name\":\"Uroonkoloji Bulteni-Bulletin of Urooncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2016-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Uroonkoloji Bulteni-Bulletin of Urooncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/UOB.666\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Uroonkoloji Bulteni-Bulletin of Urooncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/UOB.666","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 3